- Details
- Description
-
Packaging Size30t/bottle
-
Strength0.8mg&2.5mg&5.5mg&9mg&14.5mg&17.2mg
-
CompositonOrforglipron
-
Treatmentchronic weight management and Type 2 diabetes
-
FormTablet
-
BrandLuciOrfor
-
Quantity Unit0.8mg&2.5mg&5.5mg&9mg&14.5mg&17.2mg*30t/Box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Orforglipronis
Orforglipronis a once-daily, oral, non-peptide GLP-1 receptor agonist .Unlike peptide-based GLP-1 drugs (which often require strict fasting before taking and need injections), orforglipron is a small, chemically stable molecule. This means it can be taken orally as a tablet at any time, with or without food, without compromising its absorption.
Weight Management
Indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults who are overweight in and have at least 1 weight-related comorbid condition
Start with low dose and gradually escalate to reduce risk of gastrointestinal (GI) adverse reactions
Dosage escalation
- Starting dose: 0.8 mg PO once daily for at least 30 days
- After ≥30 days on 0.8 mg/day: Increase to 2.5 mg PO once daily for at least 30 days
- After ≥30 days on 2.5 mg/day: Increase to 5.5 mg PO once daily
- May increase to next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on current dose, based on treatment response and tolerability
- Not to exceed 17.2 mg/day
Dosage Modifications
Coadministration with strong CYP3A4 inhibitors
- Maximum orforglipron dose: 9 mg/day
- Avoid if coadministered with strong CYP3A4 inhibitors that also inhibit OATP1B
Coadministration with strong or moderate CYP3A4 inducers
- Strong CYP3A inducers: Avoid
- Moderate CYP3A inducers: Monitor orforglipron effectiveness and escalate dose if needed;
Renal impairment
- Renal impairment including end-stage renal disease (ESRD): No change in orforglipron pharmacokinetics observed
Hepatic impairment
- Mild-to-moderate (Child-Pugh class A or B): No dosage modification recommended
- Severe (Child-Pugh class C): No recommended
